Glenmark Pharma Q2 profit rises on strong India business performance

Quick Summary:

The company also reported a 14.6 per cent rise in revenues in the European market to Rs 687.4 crore, while recording a 1.

Glenmark also filed one abbreviated new drug application (ANDA) and launched four new products in the North America region.

On Thursday, Glenmark Pharma’s shares declined by 0.44 per cent, ending the day’s trade at Rs 1,531.70 apiece on the BSE.

---

More Pictures

---

Read Quick SummarySave Time

or

Article Details

Category: BusinessFinance

Markets: India

Topics: Glenmark Glenmark Pharmaceuticals Q2 results Pharma Companies

Source Website Secure: Yes (HTTPS)

News Sentiment: Neutral

Fact Checked: Legitimate

Article Type: News Report

Published On: 2024-11-14 @ 21:24:24 (7 hours ago)

News Timezone: GMT +5:00

News Source URL: business-standard.com

Language: English

Article Length: 399 words

Reading Time: 3 minutes read

Sentences: 15 lines

Sentence Length: 27 words per sentence (average)

Platforms: Desktop Web, Mobile Web, iOS App, Android App

Copyright Owner: © Business Standard

News ID: 23588483

View Article Analysis

About Business Standard

Main Topics: BusinessFinance

Official Website: business-standard.com

Update Frequency: 283 posts per day

Year Established: 1975

Headquarters: India

News Last Updated: 5 hours ago

Coverage Areas: India

Ownership: Independent Company

Publication Timezone: GMT +5:00

Content Availability: Worldwide

News Language: English

RSS Feed: Available (XML)

API Access: Available (JSON, REST)

Website Security: Secure (HTTPS)

Publisher ID: #49

Publisher Details

Frequently Asked Questions